Nhat Hung Benjamin Lam, Kiera Liblik
1. In this randomized controlled trial, an oral orexin receptor 2 (OX2R) agonist (TAK-994) was associated with improvements in wakefulness, sleepiness, and cataplexy incidence among patients with narcolepsy type 1.
2. TAK-994 was also associated with liver enzyme elevation and drug-induced hepatotoxicity.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Narcolepsy is a rare chronic disorder of the central nervous system resulting in excessive daytime sleepiness, disrupted nighttime sleep, and cataplexy...
September 5, 2023: 2 Minute Medicine